FLT3 and acute myeloid leukemia: Building on multicenter experience from the Turkish AML Registry, where molecular testing and access to FLT3-targeted therapy were heterogeneous, forthcoming phases should emphasize centralized genomic analysis, harmonized MRD monitoring, and systematic evaluation of real-world access barriers [72].